Randomised Open Label Trial of Hypertonic Saline and Carbocisteine in Bronchiectasis (CLEAR)
Status:
Recruiting
Trial end date:
2022-08-31
Target enrollment:
Participant gender:
Summary
Patients with bronchiectasis (BE) suffer from a persistent cough, daily sputum expectoration,
recurrent chest infections, and a poor health-related quality of life. Current guidelines for
the management of BE highlight the lack of evidence to recommend mucoactive agents, such as
hypertonic saline (HTS) and carbocisteine, to aid sputum-removal as part of standard care.
The investigators hypothesise that mucoactive agents (HTS or cabocisteine, or a combination
of both) are effective in reducing exacerbations over a 52-week period, compared to usual
care.